Phillip A. Dennis
AVEO Oncology (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, PI3K/AKT/mTOR signaling in cancer, Cancer Genomics and Diagnostics, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer(2017)4,427 cited
- → Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC(2018)2,750 cited
- → Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes(2008)2,026 cited
- Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.(2001)
- → Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations(2008)803 cited
- → PTEN loss in the continuum of common cancers, rare syndromes and mouse models(2011)792 cited
- → Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer(2015)771 cited
- Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.(2002)
- → Activation of the PI3K/Akt pathway and chemotherapeutic resistance(2002)581 cited
- → Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study(2018)570 cited